Corporate
-
New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia
Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review -
New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO®Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits
Findings Add to Existing Research Showing XARELTO® Cost-Savings Value Across Multiple Indications -
Johnson & Johnson Announces Definitive Agreement To Collaborate With Google To Advance Surgical Robotics
Strategic Collaboration Designed to Develop New Technologies that Offer Surgeons and Health Care Systems Greater Accuracy, Cost Efficiency and Better Outcomes for Patients -
Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression
Independent Data Monitoring Committee determines HELIOS study meets its primary endpoint of progression-free survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma at a pre-planned interim analysis -
Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience
New Patient Athlete™ Program Demonstrates Comprehensive Approach to Driving Sustained Behavior Change and Improved Outcomes -
Janssen Launches Three New Research Platforms Focused on Redefining Healthcare
New Focus in Disease Prevention, Disease Interception, and the Microbiome to Propel Scientific Innovation -
Depuy Synthes Companies Acquires Olive Medical Corporation
Visualization Platform Technology and Expertise to Broaden Arthroscopy Portfolio -
-
Johnson & Johnson Partners with Save the Children to Help Millions of Children over the Next Three Years
Save the Children named as Enterprise Wide Global Partner
